DocDollars

Rapid Pathogen Screening, Inc.

CA · United States · Reporting entity ID 100000010778

Total reported 2019–2025
$27.7M
#259 of 2,960 reporting companies — 0% of all reported industry payments
$0 in general payments across 0 records, plus $1.45M in research funding across 106 records.

How it breaks down

Research funding $1,445,336
Ownership & investment $26,237,244

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Rapid Pathogen Screening, Inc. reported $27.7M to US doctors and teaching hospitals from 2019 to 2025, ranking #259 of 2,960 reporting companies. 5% of that was research funding and 95% general payments such as consulting, speaking, food and travel. 0 general payment records and 106 research records were filed.

Common questions about Rapid Pathogen Screening, Inc.

How much has Rapid Pathogen Screening, Inc. paid US doctors?

Rapid Pathogen Screening, Inc. reported $27,682,580 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $0 in general payments, $1,445,336 in research funding and $26,237,244 in ownership and investment interests.

How does Rapid Pathogen Screening, Inc. rank among drug and device companies?

It ranks #259 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Rapid Pathogen Screening, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.